INS 1
Alternative Names: D-chiro-inositolLatest Information Update: 25 Sep 2021
At a glance
- Originator Insmed
- Developer Insmed; Taisho Pharmaceutical
- Class Cyclohexanes; Small molecules; Sugar alcohols
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia; Polycystic ovary syndrome; Type 2 diabetes mellitus
Most Recent Events
- 23 Sep 2002 Discontinued - Phase-II for Hyperlipidaemia in USA (PO)
- 23 Sep 2002 Discontinued - Phase-I for Type-2 diabetes mellitus in United Kingdom (PO)
- 23 Sep 2002 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)